A new screening algorithm for preeclampsia will be covered in a clinical study setting in Norway

Norway has established a framework called the "New Method" for introducing innovations into the health care system. In this framework, all innovations should undergo either a national or hospital-based health technology assessment (HTA) before being funded.

A new preeclampsia screening algorithm has been evaluated within the "New Method" framework since 2021. The algorithm helps to predict the risk of preeclampsia in the first trimester based on several parameters, such as maternal characteristics, blood pressure, ultrasound examination that includes blood flow in arteries to the uterus, and measurement of a protein biomarker (PlGF; Placenta Growth Factor). In November 2022, the method assessment phase was completed, and the National Institute of Public Health (NIPH) report was published.

In March 2023, the Decision Forum for "New Method" was held. Based on the recommendations from HTA, the following decision was made:

• To carry out an implementation study of screening for preeclampsia using an algorithm and subsequent prophylaxis with acetylsalicylic acid. The study should have a particular focus on resource-related and organizational conditions;
• Preparing proposals for the design and carrying out the study is commissioned to the Center for Fetal Diagnostics at St. Olav's Hospital;
• The decision regarding the introduction of the method will be based on the implementation study results.

See more details in Norwegian here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.